reports
Travis Perkins: TR1 Notification of Major Share Interest
Travis Perkins (TPK) Travis Perkins: TR1 Notification of Major Share Interest 09-May-2024 / 07:08 GMT/BST TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BK9RKT01 Issuer Name TRAVIS PERKINS PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments 3. Details of person subject to the notification obligation Name Bank of America Corporation City of registered office (if applicable) Country of registe...
Napco Security Technologies Inc: 1 director
A director at Napco Security Technologies Inc sold 250,000 shares at 44.202USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
Carvana Co: 4 directors
Five Directors at Carvana Co sold/sold after exercising options 209,914 shares at between 113.390USD and 125.080USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the ...
Atlassian Corp: 2 directors
A director at Atlassian Corp sold 8,241 shares at 183.464USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Palomar Holdings Inc: 1 director
A director at Palomar Holdings Inc bought 1,000 shares at 84.324USD and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Datadog Inc: 1 director
A director at Datadog Inc sold 85,637 shares at 125.412USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
- Cedric Rossi
Mister Spex: Q1 numbers less negative than feared; trends improved in ...
Yesterday, Mister Spex posted reassuring Q1 numbers considering the negative calendar effect for prescription (i.e. Earlier Easter) and demanding comparison base in Germany. Against signs of an acceleration in April, management reiterated the FY24 sales and margin outlook, as well as a sequential i
Robinhood Markets Inc: 1 director
A director at Robinhood Markets Inc sold/sold after exercising options 250,000 shares at 17.927USD and the significance rating of the trade was 99/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dire...
Lemaitre Vascular Inc: 2 directors
A director at Lemaitre Vascular Inc sold 123,206 shares at 75.480USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Laureate Education Inc: 1 director
A director at Laureate Education Inc sold 2,114,928 shares at 14.640USD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Delphine Brault
- Quentin Borie
Siemens Energy AG : Momentum at Grid Technologies boosts Q2 results
>Q2 2023-24: a very good quarter thanks to Grid Technologies - Yesterday morning, Siemens Energy published Q2 results that beat expectations, primarily thanks to the Grid Technologies division. Order intake was € 9.5bn, -22% l-f-l (of which -76% for Siemens Gamesa, -21% for Gas Services, +27% for Grid Technologies). Sales were € 8.3bn, +3.7% l-f-l (-6% for GS, +25% for GT, -4.6% for Siemens Gamesa). Adjusted EBITA (before SI – special items) was € 170m, well above for...
- Martial Descoutures
- Oussema Denguir
Medincell : De nouvelles données positives de la phase 3 de mdc-TJK
>Données de sécurité positives et une efficacité confirmée - Medincell et son partenaire Teva ont communiqué hier à la mi-journée une mise à jour de leur étude de phase 3 SOLARIS évaluant mdc-TJK (olanzapine) pour le traitement des épisodes psychotiques chez les patients souffrants de schizophrénie. Le profil de sécurité, point important de l’étude, ressort positif avec 0 cas de PDSS (Post-injection delirium/sedation syndrome) rapporté après le dosage de 80% des 3600 ...
Genel Energy PLC: Trading and operations update
Genel Energy PLC (GENL) Genel Energy PLC: Trading and operations update 09-May-2024 / 07:00 GMT/BST 9 May 2024 Genel Energy plc Trading and operations update Genel Energy plc ('Genel' or 'the Company') issues the following trading and operations update relating to Q1 2024, ahead of the Company's Annual General Meeting, which is being held today. Paul Weir, Chief Executive of Genel, said: “We have achieved balanced income and expenditure in the first quarter of the year, which is ahead of schedule. Local sales from the Tawke licence have been robust to date, with the sa...
Cairn Homes Plc: Transaction in Own Shares
Cairn Homes Plc (CRN) Cairn Homes Plc: Transaction in Own Shares 09-May-2024 / 07:00 GMT/BST 09 May 2024 Cairn Homes plc (the “Company”) Transaction in own shares The Company announces that on 8th of May 2024 it purchased a total of 100,000 of its ordinary shares of EUR 0.001 each (the "ordinary shares") on Euronext Dublin and the London Stock Exchange through the Company's broker Goodbody Stockbrokers UC (“Goodbody”), as detailed below. The repurchased shares will be cancelled. Euronext Dublin London Stock Exchange Number of or...
- Stephane Beyazian
IONOS : A robust Q1 2024 and a cloud contract that opens up prospects
>Positive impact of Q1 2024 on estimates - Following an excellent Q1 2024, we are marginally raising our forecasts as of 2025 (except 2024 due to a non-cash impact of the derivative contract for € 8bn):We factor in the cloud contract with the government agencies (ITZBund) that enable a ramp-up in revenues as of 2025 (revenues forecast at over € 20m per year over 5 years). We now expect 17% over CAGR growth in 2023-2026 vs 13% previously.We are slightly rais...
- Louis Boujard
- CFA
- Philippe Ourpatian
Endesa : Q1 2024 in line and 2024 trajectory confirmed
>Outperform recommendation reiterated and target price of € 25.3 unchanged - Q1 2024 results were broadly in line with our forecasts and those of the consensus. Restated for elements relative to the energy tax in Spain, the performance was in line with the strategic trajectory delivered during the last strategic plan delivered in November 2023, covering the 2024-2026 period. The group confirmed its 2024 guidance. The wait-and-see position on the 2026 coverage of its e...
- Anis Zgaya
- Louis Boujard
- CFA
SMA Solar Technology AG : The company believes in its lucky star, but ...
>Weak Q1 earnings as expected, saved by divestment capital gains - SMA reported yesterday morning Q1 2024 earnings that beat the consensus collected by the company on a reported basis, but below when restated for the divestment capital gain of € 19m on its subsidiary Elexon. In detail, sales came to € 362m, below forecasts (consensus at € 392m and our estimates at € 420m). EBITDA stood at € 50m (-17%), above the consensus of € 44m and in line with our forecasts of €...
- Martin Marandon-Carlhian
- Stephane Houri
Arm Holdings plc : Avec cette valorisation, des résultats > aux attent...
>Résultats T4 24 > aux attentes, tirés par des royalties et des licences également nettement > aux attentes - Le CA du T4 24 ressort à 928 M$ soit +47% yoy, > au consensus de 881 M$ et une guidance de 850/900 M$ soit un point moyen de 875 M$. Cette performance s’explique notamment par des royalties de 514 M$ à +37% yoy (après +11% au T3), > au consensus de 505 M$, reflétant une pénétration accrue de ARMv9, avec notamment une forte croissance sur le marché des smartpho...
- Martial Descoutures
- Oussema Denguir
Medincell : New positive data from phase III of mdc-TJK
>Positive safety data and confirmed efficacy - At midday yesterday, Medincell and its partner Teva provided an update on their phase III SOLARIS study evaluating mdc-TJK (olanzapine) for the treatment of psychotic episodes in patients with schizophrenia. The safety profile, an important aspect of the study, was positive, with 0 cases of PDSS (post-injection delirium/sedation syndrome) reported after dosing 80% of the 3,600 injections required for the study. The effica...
Lleida.net obtains its eighth patent in the United States for a new el...
Lleida.net obtains its eighth patent in the United States for a new electronic contracting method Madrid, 9 May. The United States Patent and Trademark Office (USTPO) has granted Lleida.net (BME:LLN) (EPA:ALLLN) (OTCQX:LLEIF) its eighth patent in the country, which corresponds this time to a new electronic contracting method. The patent, which has the number 11,973,881 and is valid for 20 years, will allow the company to market, exclusively in the USA, the new method of signing contracts, which is characterized by the encryption of the data, thus preventing the possibility of internal le...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.